PL2091530T3 - Kompozycja hamująca aktywność oksydazy nadph - Google Patents
Kompozycja hamująca aktywność oksydazy nadphInfo
- Publication number
- PL2091530T3 PL2091530T3 PL07862004T PL07862004T PL2091530T3 PL 2091530 T3 PL2091530 T3 PL 2091530T3 PL 07862004 T PL07862004 T PL 07862004T PL 07862004 T PL07862004 T PL 07862004T PL 2091530 T3 PL2091530 T3 PL 2091530T3
- Authority
- PL
- Poland
- Prior art keywords
- composition
- oxidase activity
- nadph oxidase
- inhibiting nadph
- inhibiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85855906P | 2006-11-13 | 2006-11-13 | |
EP07862004.4A EP2091530B1 (en) | 2006-11-13 | 2007-11-13 | Composition for inhibiting nadph oxidase activity |
PCT/US2007/023887 WO2008063514A1 (en) | 2006-11-13 | 2007-11-13 | Composition for inhibiting nadph oxidase activity |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2091530T3 true PL2091530T3 (pl) | 2018-01-31 |
Family
ID=39430013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07862004T PL2091530T3 (pl) | 2006-11-13 | 2007-11-13 | Kompozycja hamująca aktywność oksydazy nadph |
Country Status (8)
Country | Link |
---|---|
US (1) | US8709434B2 (pl) |
EP (3) | EP2091530B1 (pl) |
CN (2) | CN105520938A (pl) |
CA (1) | CA2668757C (pl) |
ES (1) | ES2608659T3 (pl) |
HK (1) | HK1224181A1 (pl) |
PL (1) | PL2091530T3 (pl) |
WO (1) | WO2008063514A1 (pl) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2166010A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
US8962570B2 (en) * | 2011-05-17 | 2015-02-24 | University of Pittsburgh—of the Commonwealth System of Higher Education | Therapeutic use of peptide inhibitors of NADPH oxidase; aerosolization as a delivery mechanism |
CU23963B1 (es) * | 2011-07-01 | 2013-12-11 | Ct De Ingeniería Genética Y Biotecnología | Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas |
WO2013136277A1 (en) | 2012-03-13 | 2013-09-19 | Unimark Remedies Ltd. | Pharmaceutical compositions for treatment of cardiovascular diseases |
CN103585265A (zh) * | 2013-11-27 | 2014-02-19 | 张俊 | 治疗帕金森综合症的药酒 |
CN105998048A (zh) * | 2016-05-13 | 2016-10-12 | 重庆纳德福实业集团股份有限公司 | 一种治疗缺血性脑中风的药物组合物及其制备方法与用途 |
US20190314302A1 (en) * | 2016-11-15 | 2019-10-17 | Vanderbilt University | Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension |
CN112611819B (zh) * | 2020-12-30 | 2022-09-06 | 上海日馨医药科技股份有限公司 | 一种苯磷硫胺原料及其制剂中有关物质的测定方法 |
CN113293190B (zh) * | 2021-07-27 | 2021-10-29 | 中国科学院烟台海岸带研究所 | 藻胆素结合肽及其应用 |
CA3228718A1 (en) * | 2021-09-24 | 2023-03-30 | Bonafide Health, Llc | Compositions and uses of oligo-chromopeptides and methods of making |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5865216A (ja) * | 1981-09-16 | 1983-04-18 | Dainippon Ink & Chem Inc | 抗腫瘍剤 |
JPS6013709A (ja) | 1983-07-01 | 1985-01-24 | Nippon Carbide Ind Co Ltd | 新規な化粧品添加物 |
US5047395A (en) * | 1990-07-17 | 1991-09-10 | Nagase Co., Ltd. | Reduction of oxyradical damage in biomedical applications |
US6887260B1 (en) * | 1998-11-30 | 2005-05-03 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US20030032634A1 (en) * | 2001-06-01 | 2003-02-13 | Piganelli Jon D. | Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance |
EP1404318A2 (en) | 2000-11-10 | 2004-04-07 | The President and Fellows of Harvard College | Compounds and methods for regulating cell differentiation |
WO2004013311A2 (en) * | 2002-08-06 | 2004-02-12 | Diadexus, Inc. | Compositions and methods relating to ovarian specific genes and proteins |
US7795397B2 (en) * | 2004-05-06 | 2010-09-14 | The Regents Of The University Of California | Red and near infrared flourescent phyotochrome |
US20060083727A1 (en) * | 2004-07-15 | 2006-04-20 | Nanobac Pharmaceuticals, Inc. | Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation |
PL2032122T3 (pl) * | 2006-06-27 | 2016-12-30 | Wyciągi z Aphanizomenonu Flos Aquae (AFA Klamath), aktywne związki i ich zastosowania |
-
2007
- 2007-11-13 CN CN201510492944.XA patent/CN105520938A/zh active Pending
- 2007-11-13 EP EP07862004.4A patent/EP2091530B1/en active Active
- 2007-11-13 US US12/514,578 patent/US8709434B2/en active Active
- 2007-11-13 EP EP16183435.3A patent/EP3111933B1/en not_active Not-in-force
- 2007-11-13 ES ES07862004.4T patent/ES2608659T3/es active Active
- 2007-11-13 PL PL07862004T patent/PL2091530T3/pl unknown
- 2007-11-13 CN CN200780045897A patent/CN101677992A/zh active Pending
- 2007-11-13 EP EP19194976.7A patent/EP3597188A1/en not_active Withdrawn
- 2007-11-13 CA CA2668757A patent/CA2668757C/en active Active
- 2007-11-13 WO PCT/US2007/023887 patent/WO2008063514A1/en active Application Filing
-
2016
- 2016-10-27 HK HK16112404.7A patent/HK1224181A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3111933A1 (en) | 2017-01-04 |
US20100172971A1 (en) | 2010-07-08 |
EP2091530A1 (en) | 2009-08-26 |
CA2668757A1 (en) | 2008-05-29 |
CN101677992A (zh) | 2010-03-24 |
WO2008063514A1 (en) | 2008-05-29 |
EP3111933B1 (en) | 2019-09-04 |
HK1224181A1 (zh) | 2017-08-18 |
US8709434B2 (en) | 2014-04-29 |
EP2091530A4 (en) | 2010-08-04 |
CN105520938A (zh) | 2016-04-27 |
CA2668757C (en) | 2016-08-23 |
EP3597188A1 (en) | 2020-01-22 |
ES2608659T3 (es) | 2017-04-12 |
EP2091530B1 (en) | 2016-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1224181A1 (zh) | 抑制 氧化酶活性的組合物 | |
HK1220208A1 (zh) | 用於酶抑制的化合物 | |
GB0619753D0 (en) | Enzyme inhibitors | |
EP2083074A4 (en) | MODIFIED FLAVIN-ADENINE-DINUCLEOTIDE-DEPENDENT GLUCOSE-DEHYDROGENASE | |
HK1179871A1 (en) | Pyrazolo pyridine derivatives as nadph oxidase inhibitors nadph | |
ZA201000318B (en) | Inhibitors of 11b-hydroxysteroid dehydrogenase | |
EP1978975A4 (en) | COMPOSITION FOR INHIBITING ADHESION | |
HK1112463A1 (en) | Imidazo- and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i | |
IL194339A0 (en) | Enzyme inhibitors | |
IL197714A0 (en) | 2-pyridinecarboxamide derivative having gk-activating activity | |
EP1991200A4 (en) | FLUORCHINOLONZUSAMMENSETZUNGEN | |
WO2009003090A9 (en) | Compositions and methods for inhibiting viral and bacterial activity | |
GB0608821D0 (en) | DHFR enzyme inhibitors | |
EP1969372A4 (en) | METHOD AND COMPOSITIONS FOR DETECTING ENZYMATIC ACTIVITY | |
GB0608844D0 (en) | Enzyme inhibitors | |
EP1923402A4 (en) | PROCESS FOR DETERMINING ENZYME ACTIVITY | |
EP2034019A4 (en) | COMPOSITION FOR THE NUCLEENIC ACID INTRODUCTION | |
GB0617161D0 (en) | Enzyme inhibitors | |
ZA200805723B (en) | Enzyme and photobleach containing compositions | |
GB0708221D0 (en) | Corrosion-inhibiting composition | |
GB0620884D0 (en) | Enzyme inhibitors | |
GB0612544D0 (en) | Enzyme inhibitors | |
GB0624958D0 (en) | Enzyme inhibitors | |
ZA200808237B (en) | Enzyme inhibitors | |
GB0600862D0 (en) | Enzyme |